What the FDA labels say about taking them together
Nelfinavir and palbociclib
Palbociclib's FDA label of July 2, 2026 names nelfinavir in its drug interactions section; the nelfinavir label PlainMeds reads does not name palbociclib. The palbociclib label: “Avoid concomitant use of strong CYP3A inhibitors.”
Check it at the source: the nelfinavir FDA label on DailyMed (effective December 11, 2025, AGOURON); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the nelfinavir label say about palbociclib?
Nelfinavir's label (effective December 11, 2025) does not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VIRACEPT), AGOURON, effective December 11, 2025 (SPL set e72c2bc6-9462-4a2e-8e1d-b97592376cbd), via openFDA; the full label on DailyMed
What does the palbociclib label say about nelfinavir?
Palbociclib label, drug interactionsAvoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole).
Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nelfinavir | Palbociclib | |
|---|---|---|
| Labeled for | HIV | Breast cancer |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once